NS
RXRX icon

NBC Securities’s Recursion Pharmaceuticals RXRX Stock Holding History

NBC Securities’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$11 – 2141
2024
Q4 		$11 Sell
1
-1,709
-100% -$11.5K ﹤0.01% 1200
2024
Q3 		$11K Hold
1,710
– – ﹤0.01% 1704
2024
Q2 		$12K Buy
+1,710
New +$14.9K ﹤0.01% 1622

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

NBC Securities's RXRX Position: Q1 2025 in Review

NBC Securities sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 1 share — an estimated $11 sold.

NBC Securities first reported a position in RXRX in Q2 2024 and held it in 3 quarters. The position peaked at $12K in Q2 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • NBC Securities reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • NBC Securities sold 1 Recursion Pharmaceuticals share in Q1 2025, an estimated $11.
  • NBC Securities first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • NBC Securities's Recursion Pharmaceuticals position peaked at $12K in Q2 2024.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on NBC Securities's 13F filing for Q1 2025, filed 9 Apr 2025.